Tag: acceleron pharma

November 8, 2019

Celgene Receives FDA Approval for REBLOZYL

REBLOZYL is the first FDA-approved treatment of anemia in adults with beta thalassemia that require red blood cell transfusions.
April 5, 2019

Celgene and Acceleration Pharma Announce Submission of Luspatercept Biologics License Application to FDA

Celgene (NASDAQ:CELG) and Acceleron Pharma (NASDAQ:XLRN) have announced that Celegene has submitted a biologics license application for luspatercept, which is...
June 29, 2018

Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study

Celgene (NASDAQ: CELG) and Acceleron Pharma (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study...